Prostate-Specific Antigen: What's New in 1997

Jürgen Pannek, Alan Wayne Partin

Research output: Contribution to journalArticle

Abstract

When used alone, prostate-specific antigen (PSA) is not sufficiently sensitive or specific to consider it an ideal tool for the early detection or staging of prostate cancer. To optimize the use of PSA, the concepts of PSA velocity, PSA density, and age-related PSA values were developed. Although PSA velocity provides excellent results, its determination requires three PSA values over a 2-year period. The value of PSA density rests on the accurate determination of prostatic volume by transurethral ultrasound (TRVS), which is examiner-dependent. Age-specific reference ranges appear to be more sensitive in men under age 60 than in those over 60. The molecular forms of PSA, especially the percentage of free PSA, seem to be useful tools for the detection of prostate cancer in men with slightly elevated total PSA. New molecular techniques., such as the reverse transcriptase-polymerase chain reaction (RT-PCR), enable the detection of minimal amounts of PSA messenger RNA (mRNA). Human kallikrein 2 (hK2), a serine protease closely related to PSA that also is expressed predominantly in the prostate, may be a new marker for prostate cancer.

Original languageEnglish (US)
Pages (from-to)1273-1278
Number of pages6
JournalOncology
Volume11
Issue number9
StatePublished - 1997

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Tissue Kallikreins
Serine Proteases
Reverse Transcriptase Polymerase Chain Reaction
Prostate
Reference Values

ASJC Scopus subject areas

  • Oncology

Cite this

Prostate-Specific Antigen : What's New in 1997. / Pannek, Jürgen; Partin, Alan Wayne.

In: Oncology, Vol. 11, No. 9, 1997, p. 1273-1278.

Research output: Contribution to journalArticle

Pannek, J & Partin, AW 1997, 'Prostate-Specific Antigen: What's New in 1997', Oncology, vol. 11, no. 9, pp. 1273-1278.
Pannek, Jürgen ; Partin, Alan Wayne. / Prostate-Specific Antigen : What's New in 1997. In: Oncology. 1997 ; Vol. 11, No. 9. pp. 1273-1278.
@article{9a43d648e4734bad9e26b9ccdc1415cd,
title = "Prostate-Specific Antigen: What's New in 1997",
abstract = "When used alone, prostate-specific antigen (PSA) is not sufficiently sensitive or specific to consider it an ideal tool for the early detection or staging of prostate cancer. To optimize the use of PSA, the concepts of PSA velocity, PSA density, and age-related PSA values were developed. Although PSA velocity provides excellent results, its determination requires three PSA values over a 2-year period. The value of PSA density rests on the accurate determination of prostatic volume by transurethral ultrasound (TRVS), which is examiner-dependent. Age-specific reference ranges appear to be more sensitive in men under age 60 than in those over 60. The molecular forms of PSA, especially the percentage of free PSA, seem to be useful tools for the detection of prostate cancer in men with slightly elevated total PSA. New molecular techniques., such as the reverse transcriptase-polymerase chain reaction (RT-PCR), enable the detection of minimal amounts of PSA messenger RNA (mRNA). Human kallikrein 2 (hK2), a serine protease closely related to PSA that also is expressed predominantly in the prostate, may be a new marker for prostate cancer.",
author = "J{\"u}rgen Pannek and Partin, {Alan Wayne}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "1273--1278",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9",

}

TY - JOUR

T1 - Prostate-Specific Antigen

T2 - What's New in 1997

AU - Pannek, Jürgen

AU - Partin, Alan Wayne

PY - 1997

Y1 - 1997

N2 - When used alone, prostate-specific antigen (PSA) is not sufficiently sensitive or specific to consider it an ideal tool for the early detection or staging of prostate cancer. To optimize the use of PSA, the concepts of PSA velocity, PSA density, and age-related PSA values were developed. Although PSA velocity provides excellent results, its determination requires three PSA values over a 2-year period. The value of PSA density rests on the accurate determination of prostatic volume by transurethral ultrasound (TRVS), which is examiner-dependent. Age-specific reference ranges appear to be more sensitive in men under age 60 than in those over 60. The molecular forms of PSA, especially the percentage of free PSA, seem to be useful tools for the detection of prostate cancer in men with slightly elevated total PSA. New molecular techniques., such as the reverse transcriptase-polymerase chain reaction (RT-PCR), enable the detection of minimal amounts of PSA messenger RNA (mRNA). Human kallikrein 2 (hK2), a serine protease closely related to PSA that also is expressed predominantly in the prostate, may be a new marker for prostate cancer.

AB - When used alone, prostate-specific antigen (PSA) is not sufficiently sensitive or specific to consider it an ideal tool for the early detection or staging of prostate cancer. To optimize the use of PSA, the concepts of PSA velocity, PSA density, and age-related PSA values were developed. Although PSA velocity provides excellent results, its determination requires three PSA values over a 2-year period. The value of PSA density rests on the accurate determination of prostatic volume by transurethral ultrasound (TRVS), which is examiner-dependent. Age-specific reference ranges appear to be more sensitive in men under age 60 than in those over 60. The molecular forms of PSA, especially the percentage of free PSA, seem to be useful tools for the detection of prostate cancer in men with slightly elevated total PSA. New molecular techniques., such as the reverse transcriptase-polymerase chain reaction (RT-PCR), enable the detection of minimal amounts of PSA messenger RNA (mRNA). Human kallikrein 2 (hK2), a serine protease closely related to PSA that also is expressed predominantly in the prostate, may be a new marker for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031226508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031226508&partnerID=8YFLogxK

M3 - Article

C2 - 9306417

AN - SCOPUS:0031226508

VL - 11

SP - 1273

EP - 1278

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9

ER -